

Medicare National Coverage Determination (NCD)

Topic: Screening for Hepatitis B Virus (HBV) Infection

Decision: CMS has determined that the evidence is sufficient to cover screening for HBV infection with the appropriate U.S. Food and Drug Administration (FDA) approved/cleared laboratory tests, used consistent with FDA approved labeling and in compliance with the Clinical Laboratory Improvement Act (CLIA) regulations, when ordered by the beneficiary's primary care physician or practitioner within the context of a primary care setting, and performed by an eligible Medicare provider for these services, for beneficiaries who meet the conditions as stipulated in the NCD.

What this means: Effective for claims with dates of service on and after September 28, 2016.

For more information, contact Customer Service at the number listed on your ID card.

This announcement can be found at:

<https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2017downloads/R198NCD.pdf>

Effective date: September 28, 2016